Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 150,000 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NewAmsterdam Pharma Stock Up 2.1 %

Shares of NAMS stock opened at $23.50 on Friday. The business has a 50 day moving average of $22.24 and a two-hundred day moving average of $20.43. The company has a market cap of $2.17 billion, a P/E ratio of -9.04 and a beta of -0.06. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. Analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in NewAmsterdam Pharma in the 4th quarter valued at about $50,000. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of NewAmsterdam Pharma by 6.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,571 shares of the company’s stock valued at $6,517,000 after buying an additional 14,288 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $721,000. Finally, Woodline Partners LP boosted its position in shares of NewAmsterdam Pharma by 108.7% during the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock worth $62,471,000 after buying an additional 1,266,105 shares during the period. Institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

NAMS has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reduced their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $43.80.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.